Please turn JavaScript on
Omics! Omics! icon

Omics! Omics!

Subscribe to Omics! Omics!’s news feed.

Click on “Follow” and decide if you want to get news from Omics! Omics! via RSS, as email newsletter, via mobile or on your personal news page.

Subscription to Omics! Omics! comes without risk as you can unsubscribe instantly at any time.

You can also filter the feed to your needs via topics and keywords so that you only receive the news from Omics! Omics! which you are really interested in. Click on the blue “Filter” button below to get started.

Website title: Omics! Omics!

Publisher:  keith.e.robison
Message frequency:  0.25 / day

Message History

I caught up by teleconference recently with Countable Labs CEO Giovanna Prout, fresh off Countable Labs' $26M equity fundraising - a round which was oversubscribed.  Top on my agenda: what is Prout's vision to turn that money into products.  And how will Countable balance building molecular tools vs. applying those tools to clinical problems?

Read full story
An interesting news item this week is that BioNano Genomics has appointed Alex Hastie as Chief Scientific Officer.  Hastie is an obvious choice for CSO, as for many years he was very much the public scientific face of BioNano's development.  .  But in February 2025 he left BioNano and headed to Arima Genomics.  But after a bit over a year at Arima and then a ...

Read full story
Another interesting preprint that fits several recent themes - genome minimization, discontinuation of products - comes from a Japanese group that reports on significantly reducing the genome of E.coli.  They tried for 1.7Mb but ended up settling - for now ...

Read full story
There's an interesting new preprint from Jay Shendure's lab which introduces the technique of Shred-Seq, which is a Cas3-driven approach to generating large deletions across a large eukaryotic genome.  By creating diverse collections of deletions, Shred-Seq...

Read full story
Last week brought news that Standard Biotools, which is what Fluidigm morphed into, is being acquired by Treeline Biosciences, a drug developer.  The deal values Standard at about its cash position - and Treeline made it immediately clear this is a reverse merger to grab the cash and in effect go public by also grabbing Standard's stock listing.  What Treeline has made...

Read full story